← ANALYST RATINGS · TIPRANKS
ImmunityBio (IBRX): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy0 Hold0 Sell
Ratings of 4 analysts in the last 3 months · top analysts only12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $14.25, the highest $16.00, the lowest $12.00. The average is +55.2% from the last price of $9.18.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Andres Y. Maldonado★★★★★★★★★★#149 · hits 58% · avg +42.1% | H.C. Wainwright | $15.00 | Buy | +63.4% | Reiterated | 15.10.26on TipRanks 07:14 | +0.6%next day −7.1% | ↗ |
| Jeet Mukherjee★★★★★★★★★★#655 · hits 63% · avg +26.2% | BTIG | $12.00 | Buy | +30.7% | Reiterated | 14.10.26on TipRanks Oct 15 06:10 | +2.2%next day +0.6% | ↗ |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $11.00 → $10.00−9.1% | Hold | +8.9% | Reiterated | 14.10.26on TipRanks 19:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $10.50 → $10.00−4.8% | Hold | +8.9% | Reiterated | 14.10.26on TipRanks 19:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $10.50 → $9.50−9.5% | Sell | +3.5% | Downgrade | 14.10.26on TipRanks 19:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $11.00 → $10.50−4.5% | Hold | +14.4% | Reiterated | 14.10.26on TipRanks 19:05 | — | |
| Kelly Shi★★★★★★★★★★#3014 · hits 44% · avg +5.9% | Jefferies | $12.00 → $14.00+16.7% | Buy | +52.5% | Reiterated | 14.10.26on TipRanks 16:50 | +0.6%next day −7.1% | ↗ |
| Edward Tenthoff★★★★★★★★★★#3650 · hits 41% · avg +3.5% | Piper Sandler | $12.00 → $16.00+33.3% | Buy | +74.3% | Reiterated | 14.10.26on TipRanks 15:50 | +2.2%next day +0.6% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $8.50 → $10.50+23.5% | Hold | +14.4% | Reiterated | 03.10.26on TipRanks 06:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $7.50 → $10.00+33.3% | Hold | +8.9% | Reiterated | 03.10.26on TipRanks 06:05 | — | |
| Clara Dong★★★★★★★★★★#5615 · hits 50% · avg +6.6% | Jefferies | $9.00 | Buy | −2.0% | Reiterated | 12.12.25on TipRanks 12:00 | +8.8%next day −5.8% · 5 days −12.0% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering ImmunityBio
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $13.00 at a price of $9.44 (+37.7%); now: $14.25 at $9.18 (+55.2%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 6 | 4 | 4 | 2 | 4 |
| Buy | 3 | 2 | 2 | 0 | 1 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.07 (from $-0.09 to $-0.05). Last quarter: $-0.22.
Sales
Next quarter’s sales estimate — $59M (from $56M to $66M). Last quarter: $51M.
Best top-analyst consensus in the sector · Healthcare
About ImmunityBio
- CEO: Richard Gerald Adcock
- Employees: 688
- 3530 John Hopkins Court, San Diego, CA, 92121, US
- immunitybio.com
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Data from the stock’s TipRanks forecast page, read 109 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗